Introduction: Marburg viruses are a group of negative-stranded RNA virus. It was first identified
in 1967 during a small outbreak. During that outbreak, the fatality rate increased highly and so many
people died by the Marburg virus. Later seven strains of Marburg virus were identified from those infected
humans. This virus causes Marburg Virus Disease (MVD) in human referred to as Marburg hemorrhagic
fever. Marburg virus is endemic only to Africa; however, there have been outbreaks in Europe and the
U.S.A. in recent times.
Objective: However, the Marburg virus has a high fatality rate, so a preventive measure should be taken to
prevent infection. As there is no effective therapeutic agent available against these viruses, effective vaccine
design touching all strains would be a great step for human health.
Methods: In our recent study, we used in silico analysis for designing a novel epitope-based vaccine against
all strains of Marburg virus. As it consists of several structural proteins and multiple sequence alignment
(MSA) of Glycoproteins, RNA-directed RNA polymerases, Nucleoproteins, Vp24 proteins, Vp30, Vp35, and
Vp40 proteins showed all strains of Marburg virus were conserved in RNA-directed RNA polymerase proteins.
Using that protein’s conserved region, T-cell and B-cell epitopes were determined.
Results: Among the predicted epitope, only TIGNRAPYI was found to be highly immunogenic with 100%
conservancy among all strain of human Marburg virus. The analysis also showed both types I and II major
histocompatibility complex molecules interact with this epitope and found to be nonallergenic too.
Conclusion: In vivo study of the proposed peptide is suggested for novel universal vaccine production that
might be an effective way to prevent human Marburg virus disease.